MEOBF (Mesoblast) Short Interest


MEOBF Mesoblast Ltd MEOBF
47 GF Score
Price $1.55
! 4 Warning Signs
View Full Analysis

What is Mesoblast Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEOBF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Mesoblast's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Short Interest distribution charts can be found below:

* The bar in red indicates where Mesoblast's Short Interest falls into.


MEOBF
47GF Score
Mesoblast Ltd MEOBF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
47GF Score

Get the complete analysis for MEOBF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price